<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111001</article-id><article-id pub-id-type="publisher-id">ACM-39666</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_76415512.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  ALK重排型肺癌的临床特征分析
  Analysis of Clinical Features of ALK Rearrangement Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>蕾</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>在先</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>洁</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>传玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>莒县人民医院放射科，山东 日照</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院放射科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>1</fpage><lpage>8</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨ALK重排型肺癌的临床特征，为ALK阳性肺癌患者的个体化治疗提供依据。材料及方法：选取2016年11月至2019年3月期间我院收治的104例ALK重排阳性的肺癌患者作为阳性组，另随机选取172例ALK重排阴性的肺癌患者作为阴性组，回顾性分析ALK阳性患者的临床特征，数据采用SPSS 26.0软件进行统计分析。结果：ALK阳性组与ALK阴性组在年龄、吸烟史、病理类型、转移情况和TNM分期方面，差别具有统计学意义(P &lt; 0.05)。ALK阳性组和EGFR阳性组患者在年龄、病理类型、转移情况以及TNM临床分期方面差异具有统计学意义(P均 &lt; 0.05)。相较于野生型患者，ALK阳性患者以更年轻的不吸烟患者多见(P &lt; 0.001)，两组患者均以女性、腺癌、周围型、易发生转移为主；ALK阳性组年轻、女性、不吸烟、腺癌、III~IV期肺癌患者比例高于野生组(P均 &lt; 0.05)，两组在原发部位以及转移情况方面差异无统计学意义(P &gt; 0.05)。结论：ALK阳性的NSCLC在年轻、不吸烟、腺癌、III~IV期临床分期患者比例较高；与EGFR突变相比，具有ALK基因重排的NSCLC的患者更年轻、更易表现为腺癌、临床分期晚、易发生转移；与野生型肺癌相比，ALK阳性的NSCLC多表现为年轻、女性、不吸烟、腺癌以及III~IV期临床分期。
    Objective: To explore the clinical characteristics of ALK rearranged lung cancer, and provide a basis for individualized treatment of ALK-positive lung cancer patients. Materials and Methods: 104 patients with ALK rearrangement-positive lung cancer admitted to our hospital from November 2016 to March 2019 were selected as the positive group, and 172 ALK-negative lung cancer patients were randomly selected as the negative group. The clinical characteristics of ALK-positive patients were analyzed retrospectively, and the data was statistically analyzed using SPSS 26.0 software. Results: The ALK-positive group and the ALK-negative group had statistically significant differences in age, smoking history, pathological type, metastasis and TNM staging (P &lt; 0.05). The ALK-positive group and the EGFR-positive group had statistically significant differences in age, pathological type, metastasis, and TNM clinical stage (P &lt; 0.05). Compared with wild-type patients, ALK-positive patients were more common in younger non-smokers (P &lt; 0.001). The two groups of patients were mainly female, adenocarcinoma, peripheral type, and prone to metastasis; ALK-positive group was young and female. The proportion of patients with lung cancer, non-smokers, adenocarcinoma, and stage III~IV lung cancer was higher than that in the wild group (P &lt; 0.05), and there was no significant difference in the primary site and metastasis between the two groups (P &gt; 0.05). Conclusion: ALK-positive NSCLC has a higher proportion of young, non-smokers, adenocarcinoma, and clinical stage III~IV patients; compared with EGFR mutations, NSCLC patients with ALK gene rearrangement are younger and more likely to develop adenocarcinoma. Compared with wild-type lung cancer, ALK-positive NSCLC is mostly young, female, non-smoker, adenocarcinoma, and stage III~IV clinical stage. 
  
 
</p></abstract><kwd-group><kwd>肺肿瘤，ALK融合基因，临床特征, Lung Neoplasms</kwd><kwd> ALK Fusion Gene</kwd><kwd> Clinical Features</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨ALK重排型肺癌的临床特征，为ALK阳性肺癌患者的个体化治疗提供依据。材料及方法：选取2016年11月至2019年3月期间我院收治的104例ALK重排阳性的肺癌患者作为阳性组，另随机选取172例ALK重排阴性的肺癌患者作为阴性组，回顾性分析ALK阳性患者的临床特征，数据采用SPSS 26.0软件进行统计分析。结果：ALK阳性组与ALK阴性组在年龄、吸烟史、病理类型、转移情况和TNM分期方面，差别具有统计学意义(P &lt; 0.05)。ALK阳性组和EGFR阳性组患者在年龄、病理类型、转移情况以及TNM临床分期方面差异具有统计学意义(P均 &lt; 0.05)。相较于野生型患者，ALK阳性患者以更年轻的不吸烟患者多见(P &lt; 0.001)，两组患者均以女性、腺癌、周围型、易发生转移为主；ALK阳性组年轻、女性、不吸烟、腺癌、III~IV期肺癌患者比例高于野生组(P均 &lt; 0.05)，两组在原发部位以及转移情况方面差异无统计学意义(P &gt; 0.05)。结论：ALK阳性的NSCLC在年轻、不吸烟、腺癌、III~IV期临床分期患者比例较高；与EGFR突变相比，具有ALK基因重排的NSCLC的患者更年轻、更易表现为腺癌、临床分期晚、易发生转移；与野生型肺癌相比，ALK阳性的NSCLC多表现为年轻、女性、不吸烟、腺癌以及III~IV期临床分期。</p></sec><sec id="s2"><title>关键词</title><p>肺肿瘤，ALK融合基因，临床特征</p></sec><sec id="s3"><title>Analysis of Clinical Features of ALK Rearrangement Lung Cancer</title><p>Lei Yang<sup>1</sup>, Zaixian Zhang<sup>1</sup>, Jie Xu<sup>2</sup>, Chuanyu Zhang<sup>1*</sup></p><p><sup>1</sup>Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Radiology, Juxian People’s Hospital, Rizhao Shandong</p><p><img src="//html.hanspub.org/file/1-1571797x5_hanspub.png" /></p><p>Received: Dec. 6<sup>th</sup>, 2020; accepted: Dec. 19<sup>th</sup>, 2020; published: Jan. 7<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-1571797x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the clinical characteristics of ALK rearranged lung cancer, and provide a basis for individualized treatment of ALK-positive lung cancer patients. Materials and Methods: 104 patients with ALK rearrangement-positive lung cancer admitted to our hospital from November 2016 to March 2019 were selected as the positive group, and 172 ALK-negative lung cancer patients were randomly selected as the negative group. The clinical characteristics of ALK-positive patients were analyzed retrospectively, and the data was statistically analyzed using SPSS 26.0 software. Results: The ALK-positive group and the ALK-negative group had statistically significant differences in age, smoking history, pathological type, metastasis and TNM staging (P &lt; 0.05). The ALK-positive group and the EGFR-positive group had statistically significant differences in age, pathological type, metastasis, and TNM clinical stage (P &lt; 0.05). Compared with wild-type patients, ALK-positive patients were more common in younger non-smokers (P &lt; 0.001). The two groups of patients were mainly female, adenocarcinoma, peripheral type, and prone to metastasis; ALK-positive group was young and female. The proportion of patients with lung cancer, non-smokers, adenocarcinoma, and stage III~IV lung cancer was higher than that in the wild group (P &lt; 0.05), and there was no significant difference in the primary site and metastasis between the two groups (P &gt; 0.05). Conclusion: ALK-positive NSCLC has a higher proportion of young, non-smokers, adenocarcinoma, and clinical stage III~IV patients; compared with EGFR mutations, NSCLC patients with ALK gene rearrangement are younger and more likely to develop adenocarcinoma. Compared with wild-type lung cancer, ALK-positive NSCLC is mostly young, female, non-smoker, adenocarcinoma, and stage III~IV clinical stage.</p><p>Keywords:Lung Neoplasms, ALK Fusion Gene, Clinical Features</p><disp-formula id="hanspub.39666-formula3"><graphic xlink:href="//html.hanspub.org/file/1-1571797x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571797x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571797x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肺癌的发病率居各种肿瘤的首位，是全球范围内与癌症相关的死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.39666-ref1">1</xref>]。非小细胞肺癌(Non-small cell lung cancer, NSCLC)占肺癌的85%~90% [<xref ref-type="bibr" rid="hanspub.39666-ref2">2</xref>]，其中肺腺癌是最常见的组织学亚型。近年来，肺癌的治疗已转向确定致癌的驱动子突变亚型 [<xref ref-type="bibr" rid="hanspub.39666-ref3">3</xref>]。在表皮生长因子受体(Epidermal growth factor receptor, EGFR)突变之后，间变性淋巴瘤激酶(Anaplastic lymphoma kinase, ALK)重排已成为第二个具有代表性的致癌驱动子突变亚型 [<xref ref-type="bibr" rid="hanspub.39666-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39666-ref5">5</xref>]。我们回顾性分析ALK重排型肺癌的患者的临床资料，从而提高对ALK重排型肺癌诊断及治疗的认识。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2016年11月至2019年3月期间我院收治的104例ALK重排阳性的肺癌患者作为阳性组，另随机选取172例ALK重排阴性的肺癌患者作为阴性组，其中，EGFR突变型113例，同时不含ALK及EGFR突变的纯野生型59例。纳入标准：① 患者病理诊断明确；② 病历资料完整。排除标准：① 未进行病理诊断；② 未进行基因检测；③ 临床病历资料缺。病理取材方法为术后病理、原发灶穿刺活检、纤维支气管镜活检、淋巴结或转移灶穿刺活检等。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>回顾性分析两组患者的临床资料，从年龄、性别、吸烟史、标本类型、组织学类型、原发部位、临床分期及EGFR基因突变情况这几个方面研究分析ALK融合基因阳性的非小细胞肺癌患者的临床特征。</p></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>采用SPSS 26.0软件进行统计学分析，计数资料用频数、百分率(%)表示，组间比较采用χ2检验，校正采用连续校正χ2检验及Fisher确切概率法，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 入组病例临床特征构成比</title><p>本研究收集了共276例病例，其中男性患者116例(42.1%)，女性患者160例(57.9%)；平均年龄为56 &#177; 11岁，&lt;60岁患者134例(48.5%)，≥60岁患者142例(51.5%)；手术标本177例(64.1%)，纤支镜活检标本19例(6.9%)，穿刺活检小标本51例(18.5%)，淋巴结活检标本13例(4.7%)，转移灶活检或其他方式16例(5.8%)；有吸烟史患者80例(29%)，无吸烟史196例(71.0%)。在276例非小细胞肺癌中，263例(95.3%)腺癌，其他病理类型13例(4.7%)；中央型肺癌有41例(14.9%)，周围型肺癌有235例(85.1%)；TNM分期为I期的病例有109例，II期有25例，III期有66例，IV期有76例；未发生转移的101例(36.6%)，发生胸内转移126例(45.7%)，发生胸外转移49例(17.7%) (见表1)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical characteristics of non-small cell lung cance</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >临床参数</th><th align="center" valign="middle" >n (构成比%)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >年龄(岁)</td><td align="center" valign="middle" >范围(x &#177; s)</td><td align="center" valign="middle" >30~81 (56 &#177; 11)</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >142 (51.5)</td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >134 (48.5)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >116 (42.1)</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >160 (57.9)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >吸烟史</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >196 (71.0)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >80 (29.0)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >病理类型</td><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >263 (95.3)</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >13 (4.7)</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >标本类型</td><td align="center" valign="middle" >手术标本</td><td align="center" valign="middle" >177 (64.1)</td></tr><tr><td align="center" valign="middle" >活检小标本</td><td align="center" valign="middle" >51 (18.5)</td></tr><tr><td align="center" valign="middle" >纤支镜活检</td><td align="center" valign="middle" >19 (6.9)</td></tr><tr><td align="center" valign="middle" >淋巴结活检</td><td align="center" valign="middle" >13 (4.7)</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >16 (5.8)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >原发部位</th><th align="center" valign="middle" >中央型</th><th align="center" valign="middle" >41 (14.9)</th></tr></thead><tr><td align="center" valign="middle" >周围型</td><td align="center" valign="middle" >235 (85.1)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >转移情况</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >101 (36.6)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >175 (63.4)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >TNM分期</td><td align="center" valign="middle" >I、II</td><td align="center" valign="middle" >134 (48.6)</td></tr><tr><td align="center" valign="middle" >III、IV</td><td align="center" valign="middle" >142 (51.4)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 入组的非小细胞肺癌的临床特征</p></sec><sec id="s7_2"><title>3.2. ALK阳性病例临床特征构成比</title><p>在104例ALK融合基因阳性的患者中，年龄30~81岁，平均年龄59 &#177; 10岁，&lt;60岁66例(63.5%)，≥60岁38例(36.5%)；男性40例(38.5%)，女性64例(61.5%)；无吸烟史83例(79.8%)，有吸烟史21例；在病理类型中，104例ALK融合基因阳性的患者全部为腺癌；原发中央型肺癌有16例(15.4%)，周围型肺癌有88例(84.6%)。TNM分期I期32例(30.8%)，II期9例(8.7%)，III期27例(26.0%)，IV期36例(34.5%)；未发生转移的30例(28.8%)，发生胸内转移54例(51.9%)，发生胸外转移20例(19.3%) (见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical characteristics of ALK positive patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >临床参数</th><th align="center" valign="middle" >n(构成比%)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >年龄(岁)</td><td align="center" valign="middle" >范围(x &#177; s)</td><td align="center" valign="middle" >30~81 (59 &#177; 10)</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >38 (36.5)</td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >66 (63.5)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >40 (38.5)</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >64 (61.5)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >吸烟史</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >83 (79.8)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >21 (20.2)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >病理类型</td><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >104 (100.0)</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >0 (0.0)</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >标本类型</td><td align="center" valign="middle" >手术标本</td><td align="center" valign="middle" >60 (57.7)</td></tr><tr><td align="center" valign="middle" >活检小标本</td><td align="center" valign="middle" >16 (15.4)</td></tr><tr><td align="center" valign="middle" >纤支镜活检</td><td align="center" valign="middle" >11 (10.6)</td></tr><tr><td align="center" valign="middle" >淋巴结活检</td><td align="center" valign="middle" >6 (5.7)</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >11 (10.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >原发部位</td><td align="center" valign="middle" >中央型</td><td align="center" valign="middle" >16 (15.4)</td></tr><tr><td align="center" valign="middle" >周围型</td><td align="center" valign="middle" >88 (84.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >转移情况</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >30 (28.8)</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >74 (71.2)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >TNM分期</td><td align="center" valign="middle" >I、II</td><td align="center" valign="middle" >41 (39.4%)</td></tr><tr><td align="center" valign="middle" >III、IV</td><td align="center" valign="middle" >63 (60.6%)</td></tr></tbody></table></table-wrap><p>表2. ALK重排阳性患者的临床特征</p></sec><sec id="s7_3"><title>3.3. ALK阳性与ALK阴性患者的临床特征之间的比较</title><p>在ALK阳性组与ALK阴性组的对比中，其临床病理特征在年龄、吸烟史、病理类型、标本类型、转移情况和TNM分期方面，差别具有统计学意义(P &lt; 0.05)，在性别和原发部位上，差别无统计学意义(P &gt; 0.05) (见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of clinical characteristics between ALK positive patients and ALK negative patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床参数</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >ALK (n = 104)</th><th align="center" valign="middle" >Non-ALK (n = 172)</th><th align="center" valign="middle" >Χ<sup>2</sup></th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >年龄(岁)</td><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >38 (36.5%)</td><td align="center" valign="middle" >104 (60.5%)</td><td align="center" valign="middle" >14.854</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >66 (63.5%)</td><td align="center" valign="middle" >68 (39.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >40 (38.5%)</td><td align="center" valign="middle" >76 (44.2%)</td><td align="center" valign="middle" >0.872</td><td align="center" valign="middle" >0.350</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >64 (61.5%)</td><td align="center" valign="middle" >96 (55.8%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >吸烟史</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >83 (79.8%)</td><td align="center" valign="middle" >113 (65.7%)</td><td align="center" valign="middle" >6.269</td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >21 (20.2%)</td><td align="center" valign="middle" >59 (34.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >病理类型</td><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >104 (100.0%)</td><td align="center" valign="middle" >159 (92.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.002<sup>a</sup></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >13 (7.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="5"  >标本类型</td><td align="center" valign="middle" >手术标本</td><td align="center" valign="middle" >60 (57.7%)</td><td align="center" valign="middle" >117 (68.0%)</td><td align="center" valign="middle" >12.223</td><td align="center" valign="middle" >0.016</td></tr><tr><td align="center" valign="middle" >活检小标本</td><td align="center" valign="middle" >16 (15.4%)</td><td align="center" valign="middle" >35 (20.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤支镜活检</td><td align="center" valign="middle" >11 (10.6%)</td><td align="center" valign="middle" >8 (4.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴结活检</td><td align="center" valign="middle" >6 (5.7%)</td><td align="center" valign="middle" >7 (4.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >11 (10.6%)</td><td align="center" valign="middle" >5 (2.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >原发部位</td><td align="center" valign="middle" >中央型</td><td align="center" valign="middle" >16 (15.4%)</td><td align="center" valign="middle" >25 (14.5%)</td><td align="center" valign="middle" >0.037</td><td align="center" valign="middle" >0.847</td></tr><tr><td align="center" valign="middle" >周围型</td><td align="center" valign="middle" >88 (84.6%)</td><td align="center" valign="middle" >147 (85.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >转移情况</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >30 (28.8%)</td><td align="center" valign="middle" >71 (41.3%)</td><td align="center" valign="middle" >4.318</td><td align="center" valign="middle" >0.038</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >74 (71.2%)</td><td align="center" valign="middle" >101 (58.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >TNM分期</td><td align="center" valign="middle" >I、II</td><td align="center" valign="middle" >41 (39.4%)</td><td align="center" valign="middle" >93 (54.1%)</td><td align="center" valign="middle" >5.566</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >III、IV</td><td align="center" valign="middle" >63 (60.6%)</td><td align="center" valign="middle" >79 (45.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. ALK重排阳性患者与阴性患者的临床特征比较</p><p>注：<sup>a</sup>Fisher精确检验。</p></sec><sec id="s7_4"><title>3.4. ALK阳性与EGFR突变和ALK/EGFR阴性患者的临床特征之间的比较</title><p>ALK阳性患者比具有EGFR突变组或野生组的患者年轻(p均为0.001)。ALK阳性组和EGFR阳性组患者在病理类型、转移情况以及TNM临床分期方面差异具有统计学意义(P均 &lt; 0.05)。相较于野生型患者，ALK阳性患者以不吸烟的者多见(P &lt; 0.001)；两组患者均以女性、腺癌、周围型、易发生转移为主。ALK阳性组年轻、女性、不吸烟、腺癌、III~IV期肺癌患者比例高于野生组(P均 &lt; 0.05)，两组在标本类型、原发部位以及转移情况方面差异无统计学意义(P &gt; 0.05) (见表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of clinical characteristics between ALK positive patients and EGFR mutation and ALK/EGFR negative patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床参数</th><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >ALK (n = 104)</td><td align="center" valign="middle" >EGFR (n = 113)</td><td align="center" valign="middle" >Non-ALK/EGFR (n = 59)</td><td align="center" valign="middle" >ALK vs EGFR</td><td align="center" valign="middle" >ALK vs Non-ALK/EGFR</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >年龄(岁)</td><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >38 (36.5%)</td><td align="center" valign="middle" >67 (59.3%)</td><td align="center" valign="middle" >37 (62.7%)</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >66 (63.5%)</td><td align="center" valign="middle" >46 (40.7%)</td><td align="center" valign="middle" >22 (37.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >40 (38.5%)</td><td align="center" valign="middle" >32 (28.3%)</td><td align="center" valign="middle" >15 (25.4%)</td><td align="center" valign="middle" >0.113</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >64 (61.5%)</td><td align="center" valign="middle" >81 (71.7%)</td><td align="center" valign="middle" >44 (74.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >吸烟史</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >83 (79.8%)</td><td align="center" valign="middle" >89 (78.8%)</td><td align="center" valign="middle" >24 (40.7%)</td><td align="center" valign="middle" >0.849</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >21 (20.2%)</td><td align="center" valign="middle" >24 (21.2%)</td><td align="center" valign="middle" >35 (59.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >病理类型</td><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >104 (100.0%)</td><td align="center" valign="middle" >106 (93.8%)</td><td align="center" valign="middle" >53 (89.8%)</td><td align="center" valign="middle" >0.015<sup>a</sup></td><td align="center" valign="middle" >0.002<sup>a</sup></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >7 (6.2%)</td><td align="center" valign="middle" >6 (10.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="5"  >标本类型</td><td align="center" valign="middle" >手术标本</td><td align="center" valign="middle" >60 (57.7%)</td><td align="center" valign="middle" >80 (70.8%)</td><td align="center" valign="middle" >37 (62.7%)</td><td align="center" valign="middle" >0.079</td><td align="center" valign="middle" >0.072</td></tr><tr><td align="center" valign="middle" >活检小标本</td><td align="center" valign="middle" >16 (15.4%)</td><td align="center" valign="middle" >19 (16.8%)</td><td align="center" valign="middle" >16 (27.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤支镜活检</td><td align="center" valign="middle" >11 (10.6%)</td><td align="center" valign="middle" >5 (4.4%)</td><td align="center" valign="middle" >3 (5.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴结活检</td><td align="center" valign="middle" >6 (5.7%)</td><td align="center" valign="middle" >5 (4.4%)</td><td align="center" valign="middle" >2 (3.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >11 (10.6%)</td><td align="center" valign="middle" >4 (3.6%)</td><td align="center" valign="middle" >1 (1.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >原发部位</td><td align="center" valign="middle" >中央型</td><td align="center" valign="middle" >16 (15.4%)</td><td align="center" valign="middle" >11 (9.7%)</td><td align="center" valign="middle" >14 (23.7%)</td><td align="center" valign="middle" >0.208</td><td align="center" valign="middle" >0.186</td></tr><tr><td align="center" valign="middle" >周围型</td><td align="center" valign="middle" >88 (84.6%)</td><td align="center" valign="middle" >102 (90.3%)</td><td align="center" valign="middle" >45 (76.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >转移情况</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >30 (28.8%)</td><td align="center" valign="middle" >48 (42.5%)</td><td align="center" valign="middle" >23 (39.0%)</td><td align="center" valign="middle" >0.037</td><td align="center" valign="middle" >0.184</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >74 (71.2%)</td><td align="center" valign="middle" >65 (57.5%)</td><td align="center" valign="middle" >36 (61.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >TNM分期</td><td align="center" valign="middle" >I、II</td><td align="center" valign="middle" >41 (39.4%)</td><td align="center" valign="middle" >60 (53.1%)</td><td align="center" valign="middle" >33 (55.9%)</td><td align="center" valign="middle" >0.044</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >III、IV</td><td align="center" valign="middle" >63 (60.6%)</td><td align="center" valign="middle" >53 (46.9%)</td><td align="center" valign="middle" >26 (44.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. ALK重排阳性患者与EGFR突变和ALK/EGFR阴性患者的临床特征比较</p><p>注：<sup>a</sup>Fisher 精确检验。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>据研究报道，在亚洲的非小细胞肺癌患者中，总ALK融合基因突变率约为3.2%，ALK阳性的发病率在肺腺癌患者中约为2%~7% [<xref ref-type="bibr" rid="hanspub.39666-ref6">6</xref>]。尽管和EGFR突变率相比，ALK阳性表达率较低，但由于中国人口基数大，肺癌发生率也较高，并且它对ALK突变肿瘤靶向治疗的效果优于传统治疗，可显著改善患者无进展生存期 [<xref ref-type="bibr" rid="hanspub.39666-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39666-ref8">8</xref>]，因此对ALK基因的检测仍为重要。</p><p>在本研究中，我们调查了具有ALK基因重排的NSCLC的临床特征。根据先前的研究 [<xref ref-type="bibr" rid="hanspub.39666-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39666-ref10">10</xref>]，ALK阳性多见于年轻、偶尔吸烟或不吸烟、腺癌的患者。在本研究的532例非小细胞肺癌患者中，平均年龄为56 &#177; 11岁，ALK阳性表达患者平均年龄为59 &#177; 10岁，其中&lt;60岁66例，≥60岁38例，其在年龄组中的差异具有统计学意义(P均 &lt; 0.05)，与多数文献报道的ALK基因阳性表达多见于年轻患者的研究结果相一致。本研究中，有吸烟史80例(29.0%)，无吸烟史196例(71.0%)，在104例ALK基因阳性患者中，有吸烟史21例(20.2%)，无吸烟史患者83例(79.8%)，与ALK阴性组及纯野生组相比，其差别具有统计学意义，与既往研究一致。本文研究结果显示104例ALK基因阳性患者病理类型均为腺癌，其差别具有统计学意义(P均 &lt; 0.05)，这与大部分的研究报道相一致。这可能是因为与其他组织学类型相比，腺癌相对容易被诱发 [<xref ref-type="bibr" rid="hanspub.39666-ref11">11</xref>]。</p><p>目前对于ALK阳性表达率在性别中存在显著差异仍具有争议，有研究 [<xref ref-type="bibr" rid="hanspub.39666-ref12">12</xref>] 显示ALK基因在性别中的表达存在显著差异，认为ALK基因阳性肺癌多为女性。但在本研究中，ALK阳性表达患者男性40例，女性64例，与ALK阴性组及EGFR阳性组相比，其差别没有统计学意义(P &gt; 0.05)，与Rizzo等 [<xref ref-type="bibr" rid="hanspub.39666-ref13">13</xref>] 的研究结果一致。另外，本研究显示ALK阳性组与纯野生组相比，差异具有统计学意义(P &lt; 0.001)。因此，性别对ALK基因重排的表达是否有影响仍需更多的研究去证实。</p><p>本研究中显示原发中央型肺癌有41例，周围型肺癌有235例，在ALK基因阳性患者中16例表现为中央型，88例表现为周围型，差别没有统计学意义(P均 &gt; 0.05)。关于ALK阳性的NSCLC患者原发好发部位研究较少，且未有明确结论，部分研究 [<xref ref-type="bibr" rid="hanspub.39666-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39666-ref15">15</xref>] 认为ALK多位于中央，与本研究结果相反，原因可能与样本大多为术后病理有关。</p><p>在本研究中，与ALK阴性型、EGFR突变型及纯野生型相比较，ALK重排型晚期更易出现转移，ALK阳性组发生转移患者比例高于ALK阴性组及EGFR突变组，差异具有统计学意义(P均 &lt; 0.05)，与先前的临床研究基本一致 [<xref ref-type="bibr" rid="hanspub.39666-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.39666-ref17">17</xref>]。</p><p>此外，有研究 [<xref ref-type="bibr" rid="hanspub.39666-ref18">18</xref>] 显示ALK基因阳性患者临床分期多为III~IV期。本研究在TNM临床分期的分析中，有60.6%的ALK基因阳性患者确诊时处于III~IV期，且ALK阳性组III~IV期肺癌患者比例高于ALK阴性组、EGFR突变组及纯野生组，其差别具有统计学意义(P = 0.018)。</p><p>本研究存在一些局限性：首先，样本量较少；其次，这是一项单中心回顾性研究，缺乏外部验证，因此会存在选择偏倚；最后，我们对比研究了ALK阳性与ALK阴性、EGFR阳性以及野生型肺癌的临床特征，未能纳入更多的基因突变类型。因此未来需要更多样本的多中心前瞻性研究，以期对ALK重排型肺癌的临床特征有更加深入的了解。</p><p>在本研究中，对276例非小细胞肺癌患者的临床特征进行分析，发现了ALK基因重排肺癌独特的临床特征：具有ALK基因重排的NSCLC在不吸烟的年轻腺癌患者中更容易发展，发现时通常为晚期；与EGFR突变相比，具有ALK基因重排的NSCLC的患者更年轻、临床分期晚、易发生转移；与野生型肺癌相比，具有ALK基因重排的NSCLC多表现为相对年轻的女性不吸烟患者，易发生转移，分期更晚。结合这些结果可能有助于临床医生评估NSCLC合并ALK基因重排的可能性，以实现肺癌的早发现、早诊断、早治疗。</p></sec><sec id="s9"><title>声 明</title><p>该研究获得相应的伦理许可。</p></sec><sec id="s10"><title>文章引用</title><p>杨 蕾,张在先,许 洁,张传玉. ALK重排型肺癌的临床特征分析Analysis of Clinical Features of ALK Rearrangement Lung Cancer[J]. 临床医学进展, 2021, 11(01): 1-8. https://doi.org/10.12677/ACM.2021.111001</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39666-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mao, Y., Yang, D., He, J., et al. (2016) Epidemiology of Lung Cancer. Surgical Oncology Clinics of North America, 25, 439-445. &lt;br&gt;https://doi.org/10.1016/j.soc.2016.02.001</mixed-citation></ref><ref id="hanspub.39666-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2020) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.39666-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hoang, T., Myung, S.K., Pham, T.T., et al. (2020) Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials. Cancers (Basel), 12, 526.  
&lt;br&gt;https://doi.org/10.3390/cancers12030526</mixed-citation></ref><ref id="hanspub.39666-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Usmani, S., Marafi, F., Rasheed, R., et al. (2018) Targeted Therapy with Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation. Clinical Nuclear Medicine, 43, 752-754. &lt;br&gt;https://doi.org/10.1097/RLU.0000000000002220</mixed-citation></ref><ref id="hanspub.39666-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shaw, A.T., Solomon, B.J., Besse, B., et al. (2019) ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 37, 1370-1379.  
&lt;br&gt;https://doi.org/10.1200/JCO.18.02236</mixed-citation></ref><ref id="hanspub.39666-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tian, H.X., Zhang, X.C., Yang, J.J., et al. (2017) Clinical Characteristics and Sequence Complexity of Anaplastic Lymphoma Kinase Gene Fusions in Chinese Lung Cancer Patients. Lung Cancer, 114, 90-95.  
&lt;br&gt;https://doi.org/10.1016/j.lungcan.2017.11.001</mixed-citation></ref><ref id="hanspub.39666-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Du, X., Shao, Y., Qin, H.F., et al. (2018) ALK-Rearrangement in Non-Small-Cell Lung Cancer (NSCLC). Thoracic Cancer, 9, 423-430. &lt;br&gt;https://doi.org/10.1111/1759-7714.12613</mixed-citation></ref><ref id="hanspub.39666-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fan, J., Fong, T., Xia, Z., et al. (2018) The Efficacy and Safety of ALK Inhibitors in the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis. Cancer Medicine, 7, 4993-5005.  
&lt;br&gt;https://doi.org/10.1002/cam4.1768</mixed-citation></ref><ref id="hanspub.39666-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Solomon, B.J., Mok, T., Kim, D.W., et al. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. The New England Journal of Medicine, 371, 2167-2177. &lt;br&gt;https://doi.org/10.1056/NEJMoa1408440</mixed-citation></ref><ref id="hanspub.39666-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mori, M., Hayashi, H., Fukuda, M., et al. (2019) Clinical and Computed Tomography Characteristics of Non-Small Cell Lung Cancer with ALK Gene Rearrangement: Comparison with EGFR Mutation and ALK/EGFR-Negative Lung Cancer. Thoracic Cancer, 10, 872-879. &lt;br&gt;https://doi.org/10.1111/1759-7714.13017</mixed-citation></ref><ref id="hanspub.39666-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Liam, C.K., Lim, K.H. and Wong, C.M. (2000) Lung Cancer in Patients Younger than 40 Years in a Multiracial Asian Country. Respirology, 5, 355-361. &lt;br&gt;https://doi.org/10.1111/j.1440-1843.2000.00275.x</mixed-citation></ref><ref id="hanspub.39666-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Wang, S., Xu, S., et al. (2014) Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis. PLoS ONE, 9, e110617.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0110617</mixed-citation></ref><ref id="hanspub.39666-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rizzo, S., Petrella, F., Buscarino, V., et al. (2016) CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. European Radiology, 26, 32-42.  
&lt;br&gt;https://doi.org/10.1007/s00330-015-3814-0</mixed-citation></ref><ref id="hanspub.39666-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, S., Korn, R.L., Oklu, R., et al. (2014) ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization. Radiology, 272, 568-576. &lt;br&gt;https://doi.org/10.1148/radiol.14140789</mixed-citation></ref><ref id="hanspub.39666-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, H.J., Sohn, I., Cho, J.H., et al. (2015) Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. Medicine (Baltimore), 94, e1753.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000001753</mixed-citation></ref><ref id="hanspub.39666-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Park, J., Kobayashi, Y., Urayama, K.Y., et al. (2016) Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma. PLoS ONE, 11, e0161081.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0161081</mixed-citation></ref><ref id="hanspub.39666-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kim, T.H., Woo, S., Yoon, S.H., et al. (2019) CT Characteristics of Non-Small Cell Lung Cancer with Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 213, 1059-1072. &lt;br&gt;https://doi.org/10.2214/AJR.19.21485</mixed-citation></ref><ref id="hanspub.39666-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, F., Xu, M., Lei, H., et al. (2015) Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis. PLoS ONE, 10, e0117333.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0117333</mixed-citation></ref></ref-list></back></article>